Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have dramatically changed clinical outcomes in a wide variety of tumours. However, clinical response varies among patients receiving mAb-based treatm...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.926289/full |
| _version_ | 1818550026463346688 |
|---|---|
| author | Juan J. Mata-Molanes Joseba Rebollo-Liceaga Elena Mª Martínez-Navarro Ramón González Manzano Antonio Brugarolas Manel Juan Manuel Sureda |
| author_facet | Juan J. Mata-Molanes Joseba Rebollo-Liceaga Elena Mª Martínez-Navarro Ramón González Manzano Antonio Brugarolas Manel Juan Manuel Sureda |
| author_sort | Juan J. Mata-Molanes |
| collection | DOAJ |
| description | Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have dramatically changed clinical outcomes in a wide variety of tumours. However, clinical response varies among patients receiving mAb-based treatment, so it is necessary to search for predictive biomarkers of response to identify the patients who will derive the greatest therapeutic benefit. The interaction of mAbs with Fc gamma receptors (FcγR) expressed by innate immune cells is essential for antibody-dependent cellular cytotoxicity (ADCC) and this binding is often critical for their in vivo efficacy. FcγRIIa (H131R) and FcγRIIIa (V158F) polymorphisms have been reported to correlate with response to therapeutic mAbs. These polymorphisms play a major role in the affinity of mAb receptors and, therefore, can exert a profound impact on antitumor response in these therapies. Furthermore, recent reports have revealed potential mechanisms of ICIs to modulate myeloid subset composition within the tumour microenvironment through FcγR-binding, optimizing their anti-tumour activity. The purpose of this review is to highlight the clinical contribution of FcγR polymorphisms to predict response to mAbs in cancer patients. |
| first_indexed | 2024-12-12T08:40:57Z |
| format | Article |
| id | doaj.art-c4184db2acb74038845fae3fb3915c94 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T08:40:57Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c4184db2acb74038845fae3fb3915c942022-12-22T00:30:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.926289926289Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal AntibodiesJuan J. Mata-Molanes0Joseba Rebollo-Liceaga1Elena Mª Martínez-Navarro2Ramón González Manzano3Antonio Brugarolas4Manel Juan5Manuel Sureda6Oncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainOncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainOncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainOncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainOncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainDepartment of Immunology, Hospital Clínic de Barcelona, Barcelona, SpainOncology Platform, Hospital Quirónsalud Torrevieja, Alicante, SpainTherapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have dramatically changed clinical outcomes in a wide variety of tumours. However, clinical response varies among patients receiving mAb-based treatment, so it is necessary to search for predictive biomarkers of response to identify the patients who will derive the greatest therapeutic benefit. The interaction of mAbs with Fc gamma receptors (FcγR) expressed by innate immune cells is essential for antibody-dependent cellular cytotoxicity (ADCC) and this binding is often critical for their in vivo efficacy. FcγRIIa (H131R) and FcγRIIIa (V158F) polymorphisms have been reported to correlate with response to therapeutic mAbs. These polymorphisms play a major role in the affinity of mAb receptors and, therefore, can exert a profound impact on antitumor response in these therapies. Furthermore, recent reports have revealed potential mechanisms of ICIs to modulate myeloid subset composition within the tumour microenvironment through FcγR-binding, optimizing their anti-tumour activity. The purpose of this review is to highlight the clinical contribution of FcγR polymorphisms to predict response to mAbs in cancer patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.926289/fullcancer immunotherapyFc gamma receptor (FcγR)immune checkpoint inhibitorsmonoclonal Abspolymorphisms |
| spellingShingle | Juan J. Mata-Molanes Joseba Rebollo-Liceaga Elena Mª Martínez-Navarro Ramón González Manzano Antonio Brugarolas Manel Juan Manuel Sureda Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies Frontiers in Oncology cancer immunotherapy Fc gamma receptor (FcγR) immune checkpoint inhibitors monoclonal Abs polymorphisms |
| title | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies |
| title_full | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies |
| title_fullStr | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies |
| title_full_unstemmed | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies |
| title_short | Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies |
| title_sort | relevance of fc gamma receptor polymorphisms in cancer therapy with monoclonal antibodies |
| topic | cancer immunotherapy Fc gamma receptor (FcγR) immune checkpoint inhibitors monoclonal Abs polymorphisms |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.926289/full |
| work_keys_str_mv | AT juanjmatamolanes relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT josebarebolloliceaga relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT elenamamartineznavarro relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT ramongonzalezmanzano relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT antoniobrugarolas relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT maneljuan relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies AT manuelsureda relevanceoffcgammareceptorpolymorphismsincancertherapywithmonoclonalantibodies |